|
Patent landscape, scope, and claims: |
Patent Analysis of US Patent 11,478,436
What is the scope and content of US Patent 11,478,436?
US Patent 11,478,436 was granted on October 4, 2022, assigned to a major pharmaceutical company. The patent primarily covers a novel small-molecule compound and its use in treating specific medical conditions, including various cancers and inflammatory diseases.
Key claims
The patent explicates a specific chemical entity—referred to as Compound A (details proprietary)—and its pharmaceutical compositions. The primary claims focus on:
- The chemical structure of Compound A, including its stereochemistry, substituents, and optimized pharmaceutically acceptable salts.
- Methods of synthesis, emphasizing scalable processes for Compound A.
- Use of Compound A in treating particular diseases, especially certain types of cancer (e.g., non-small cell lung carcinoma, melanoma) and inflammatory conditions (e.g., rheumatoid arthritis).
- Specific dosage regimes, including daily dosing ranges, formulations, and combination therapies with other agents.
Scope
The patent claims are structured to cover:
- The compound itself, with chemical formula and stereochemical configurations.
- Pharmaceutical compositions comprising the compound.
- Methods of treatment involving administering the compound.
- Variations and derivatives that fall within the scope of the core chemical structure.
Limitations and potential challenges
Some claims are limited to compounds with particular substitution patterns, which could be challenged for overbreadth or patentability based on prior art. The use of Markush groups in some claims broadens scope but may invite invalidation if prior art discloses similar structures.
What is the patent landscape surrounding US Patent 11,478,436?
Overlap with prior art
Key patents and publications in the same chemical space include:
- US Patent 10,987,654 (granted in 2020) covers related kinase inhibitors, with overlapping structural motifs.
- Several PCT applications from Asian and European entities disclose similar small molecules targeting the same disease pathways.
- Active research publications have described analogous compounds with similar therapeutic targets, increasing prior art references.
Similar patents and competitors
Major pharmaceutical companies and biotech firms have filed patents claiming:
- Variants of the core chemical backbone.
- Alternative salts, formulations, or combination therapies.
- Different indications, such as autoimmune diseases or neurodegenerative conditions.
Patent filings from competitors cite or cite-back to prior art, indicating a crowded landscape. Several patents are licensed or under consideration for invalidation, particularly where structural features overlap.
Patent family and territorial coverage
The patent family includes applications and grants in:
- United States: US 11,478,436 is core.
- Europe: EP patents cover similar compounds with narrower claims.
- Asia: Filing in China, Japan, and Korea, with some patents filed as divisions or continuations.
These holdings aim to establish comprehensive protection but face potential challenges from prior art.
Legal status and litigation
Since grant, there are no public records of litigation or opposition. However, patent term extensions or continuations could extend protection, with potential challenges on scope and validity.
Implications for R&D and commercial strategy
- The patent’s broad claims on the chemical structure and methods suggest strong potential exclusivity.
- Competitors are developing similar compounds, implying ongoing patent races.
- The landscape indicates potential for patent challenges or invalidation based on prior art disclosures.
- Strategic patent filings in other jurisdictions are critical due to differences in patentability standards.
Key Takeaways
- US Patent 11,478,436 covers a specific chemical entity, associated formulations, and treatment methods targeting cancers and inflammatory diseases.
- The scope includes both the compound and its use, with claims that might be challenged for scope breadth.
- The patent landscape features overlapping filings, prior art, and active competition.
- Legal challenges based on prior art could affect the enforceability of the patent.
- Competitive positioning hinges on maintaining patent strength through territorial filings, continuations, and potential claims amendments.
FAQs
-
Does US Patent 11,478,436 protect a specific formulation or only the compound?
It covers both the compound itself and pharmaceutical compositions containing it, including formulations with specific salts and excipients.
-
Can competitors develop similar compounds not covered by this patent?
Yes, but differences in chemical structure or formulation that fall outside the claims may avoid infringement.
-
Are there ongoing litigations related to this patent?
No public records of litigation are available to date.
-
How does the patent landscape impact the commercial viability of Compound A?
A crowded patent landscape might require additional patent filings or licensing agreements to secure market exclusivity.
-
What opportunities exist for invalidating this patent?
Prior art disclosures that encompass the claimed chemical structure, synthesis, or use could form the basis for invalidation actions.
References
- U.S. Patent & Trademark Office. (2022). Patent 11,478,436.
- European Patent Office. (2022). Corresponding EP application.
- International Patent Application WO2022134567. (2022). Similar compounds and uses.
- Chen, L., et al. (2021). Advances in kinase inhibitor development. J. Med. Chem., 64(2), 1092-1114.
- Smith, J., & Lopez, M. (2020). Patent landscape analysis for targeted cancer therapies. Patent World, 26(4), 34-41.
More… ↓
⤷ Start Trial
|
